https://prospect.org/blogs-and-newsl...mula-shortage/
Monopolies and the Baby Formula Shortage
             Today on TAP: Four companies sell almost all baby formula in the U.S., magnifying supply shocks that cause families to scramble.
                                                                                                   by      
David Dayen 
May 10, 2022
 
        
Anthony Behar/Sipa USA via AP Images
A sign indicates low stock of baby formula at a Target store in the Queens borough of New York City, May 10, 2022.
Families are desperately hunting around drugstores and groceries for baby formula amid a 
nationwide shortage. Analyst 
Datasembly indicates that 40 percent of leading baby formula products were out of stock in late April. Yes, that 
refers to all sizes  of the same product (it’s 40 percent of the SKU numbers, not 40 percent  of all formula), but the problem shouldn’t really be minimized:  Businesses are rationing and parents are scrambling, even if switching  brands doesn’t typically carry any health consequences (though that 
isn’t always the case).
    Why is this happening, exactly? Well, there was a 
large recall of Similac, one of the major brands, in February. But I am having a hard time with the alibi of another large brand, Enfamil, which 
has claimed an “18 percent surge in demand for baby formula nationwide.”
    Was there a large influx of babies that I’m not aware of? Have they  all gotten hungrier? Contrary to myth, the pandemic and the forced  lockdowns did not lead to a baby boom; in fact, they led to a 
baby bust. U.S. births 
declined in the first half of 2021, the last point for which we have data. Even if there was an uptick later, it’s extremely unlikely to see an 18 percent surge.
    Left unsaid by formula manufacturers is their iron grip on the  market, which exacerbates supply disruptions. The shortage is a  manifestation of the same 
problems we’ve seen with the supply chain, made worse by monopoly.
    As of 2018, four companies—Abbott (which makes Similac), Reckitt  Benckiser (Enfamil), Nestlé (Gerber), and Perrigo (which makes  store-brand formula)—control about 89 percent of the U.S. market. Any  disruption to one of their products will be magnified, whether it’s a  recall for Similac or inability to source ingredients. A few companies  in the market relying on the same sources creates a much more fragile  supply chain.
    Keep in mind that baby formula consists mostly of dehydrated cow’s  milk, vitamins, and a ton of sugar. Yet it somehow costs at least $150  and 
as much as $428 a month, high enough to 
sustain a mass crime ring  even before the price jumped 18 percent over the past year. This is  probably not as distressing to the oligopolistic companies selling the  stuff as it is for families.
    Some have suggested that the Women, Infants and Children (WIC)  program is responsible for the shortages. Half of all U.S. formula  consumption goes through WIC, which 
provides free infant formula  through a competitive bidding process where states negotiate bulk  discounts in exchange for market exclusivity. But that program has been  in place since the 1980s; it cannot be responsible for the inflation  over the past year. Similarly, research has found 
little or no effect between the WIC program and higher retail prices for non-WIC families.
    The competitive bidding setup does tend to concentrate the market,  however. (It’s a bit of a chicken-or-egg problem; market concentration  may have caused few WIC bidders, not the other way around.) This is  manageable except in cases of supply shock, as we’re now seeing. The  antitrust agencies should definitely take a look.
    Meanwhile, one shouldn’t deny the fierce use of lobbying to cement  the industry’s monopoly. During the Trump administration, U.S. delegates  to the United Nations 
threatened countries with trade sanctions  and withdrawal of military aid if they supported an anodyne  international resolution in support of breastfeeding as a healthy option  for infants. That was stage-managed by the baby formula industry, which  particularly wanted to keep its lock on the developing world. The  interests of private monopolists were put ahead of public health and  security.
    The dominant companies claim to be ramping up production to solve the  shortage. It should be noted that their incentives run in the other  direction, to keep prices high by putting a lid on supply. When you’re a  monopolist, you can do that without much trouble.